Company performance
Current Price
as of Jan 21, 2025$2.48
P/E Ratio
N/A
Market Cap
$3.57M
- SEMR
Description
Salarius Pharmaceuticals, Inc. is a clinical-stage oncology company, which engages in the development of treatments for cancers with high, unmet medical need. Its pipeline includes SP-3164, a targeted protein degrader and seclidemstat (SP-2577), a targeted protein inhibitor. The company was founded in February 2014 and is headquartered in Houston, TX.
Metrics
Overview
- HQHouston, TX
- SectorHealth Technology
- IndustryBiotechnology
- TickerSLRX
- Price$2.48-7.81%
Trading Information
- Market cap$3.57M
- Float97.48%
- Average Daily Volume (1m)7,048,862
- Average Daily Volume (3m)2,151,236
- EPS-$8.19
Company
- RevenueN/A
- Rev growth (1yr)N/A
- Net income-$0.97M
- Gross marginN/A
- EBITDA marginN/A
- EBITDA-$1.01M
- EV-$1.11M
- EV/RevenueN/A
- P/EN/A
- P/SN/A
- P/B1.22
Documents
SEC Filings
Factset Street Account